Kieran Sheahan
Overview
Explore the profile of Kieran Sheahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kane L, Flood B, Manils J, McSkeane D, Smith A, Tosetto M, et al.
Gastro Hep Adv
. 2025 Jan;
4(2):100552.
PMID: 39866724
Background And Aims: Colorectal cancer (CRC) is the second most deadly cancer globally. The rapidly rising incidence rate of CRC, coupled with increased diagnoses in individuals <50 years, indicates that...
2.
Loughrey M, OConnell L, McSorley L, Martin S, Hanly A, Winter D, et al.
Fam Cancer
. 2024 Nov;
24(1):2.
PMID: 39546086
Colorectal cancer (CRC) is a common cancer in Ireland. Of all CRCs, 2-4% are attributable to Lynch Syndrome (LS), the most common CRC predisposition syndrome. LS is caused by constitutional...
3.
Kus Ozturk S, Bokhorst J, Baumann E, Sheahan K, van de Velde C, Marijnen C, et al.
Mod Pathol
. 2024 Nov;
38(2):100655.
PMID: 39522647
Owing to insufficient evidence, tumor budding (TB) is not currently evaluated in colorectal cancer (CRC) biopsies. This study investigates TB in CRC by establishing the value of intratumoral budding (ITB)...
4.
Coady L, Sheahan K, Brown I, Carneiro F, Gill A, Kumarasinghe P, et al.
Expert Rev Gastroenterol Hepatol
. 2024 Sep;
18(9):529-539.
PMID: 39268773
Introduction: Lymphocyte-rich inflammation of the esophageal mucosa has gained increased awareness among pathologists and clinicians recently. Patients usually present with symptoms of esophageal dysfunction, including dysphagia and food bolus impaction....
5.
Shepherd N, Wong N, Sheahan K
Histopathology
. 2024 Aug;
85(4):686-689.
PMID: 39108219
No abstract available.
6.
OReilly M, Krstic A, Iglesias-Martinez L, Ryan E, Moran B, Winter D, et al.
J Pers Med
. 2024 Jun;
14(6).
PMID: 38929861
Early-onset colorectal cancer (EOCRC), defined as colorectal cancer in individuals under 50 years of age, has shown an alarming increase in incidence worldwide. We report a case of a twenty-four-year-old...
7.
Aherne S, Donnelly M, Ryan E, Davey M, Creavin B, McGrath E, et al.
Histopathology
. 2024 Apr;
85(2):224-243.
PMID: 38629323
Background: Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility...
8.
Ozturk S, Martinez C, Mens D, Verhoef C, Tosetto M, Sheahan K, et al.
Histopathology
. 2024 Jan;
84(6):935-946.
PMID: 38192084
Aims: Lymph node metastases (LNM) are one of the most important prognostic indicators in solid tumours and a major component of cancer staging. Neoadjuvant therapy might influence nodal status by...
9.
Kus Ozturk S, Graham Martinez C, Sheahan K, Winter D, Aherne S, Ryan E, et al.
Histopathology
. 2023 Aug;
83(6):870-879.
PMID: 37609761
Aims: Partial response to neoadjuvant chemoradiotherapy (CRT) presents with one of two main response patterns: shrinkage or fragmentation. This study investigated the relevance of these response patterns in rectal cancer,...
10.
Beauchamp K, Moran B, OBrien T, Brennan D, Crown J, Sheahan K, et al.
Cancer Metastasis Rev
. 2023 Jul;
42(4):1189-1200.
PMID: 37394540
Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their...